Australians living with complex and debilitating conditions, including juvenile arthritis, rare liver disease and multiple sclerosis, will pay less for treatment following new Pharmaceutical Benefits Scheme (PBS) listings announced by the Albanese Government.
“The medicines we’re listing are life-changing for people with distressing and even deadly conditions,” says Minister for Health and Ageing Mark Butler.
“Without the PBS, Australian patients would pay thousands of dollars instead of the newly reduced maximum of $25 per script, or just $7.70 for those who hold a concession card.”
Broader access to Humira
The PBS expansion includes broader access to adalimumab (Humira®), which will now be subsidised for juvenile idiopathic arthritis, in addition to the other paediatric immune-mediated inflammatory diseases (IMIDs) already listed, such as Crohn’s disease, ulcerative colitis and chronic plaque psoriasis.
These conditions cause painful inflammation affecting joints, gut and skin, and can disrupt growth, schooling and daily life.
It’s said that an estimated 18,500–30,100 Australians aged 0–24 years are living with arthritis.
Without PBS support, families could face costs of approximately $650 per Humira script.
Bylvay: a first-time listing
Odevixibat (Bylvay®) will also be listed on the PBS for the first time for progressive familial intrahepatic cholestasis (PFIC), a rare genetic liver disease that primarily affects children but can also occur in adults.
PFIC causes severe itching, sleep disruption and progressive liver damage, sometimes leading to liver transplantation.
It is estimated that PFIC affects 1 in 50,000 to 1 in 100,000 live births globally.
Without the PBS subsidy, families could pay more than $200,000 per script.
A listing for MS
The listing also includes ublituximab (Briumvi®) for relapsing-remitting multiple sclerosis (RRMS).
RRMS is an autoimmune disease that affects the central nervous system and can significantly impair mobility, vision and independence.
Reportedly, in 2024, more than 14,000 patients accessed a comparable treatment through the PBS, with unsubsidised costs reaching up to $15,000 per script.
A trusted government service
“The PBS is one of the most trusted government services in Australia, and we’re committed to strengthening it by adding the latest treatments recommended by our experts,” says Minister Butler.









